DAFTAR PUSTAKA 1. Palmer J, Perunovic P, Tidy J, Review Endometrial Hyperplasia. The Obstetrician & Gynaecologist 2008;10:211 216. 2. Reed S.D, Newton K.M. et al. Incidence Of Endometrial Hyperplasia. Am J Obstet Gynecol. 2009; 200 (6): 678. 3. Montgomery B. Daum G. Dunton C. Endometrial Hyperplasia: A Review. Obstetrical and Gynecological Survey. 2004: 368-376 4. Trimble C et al. Management of Endometrial Precancers. The American Collage of Obstetricians and Gynecologist Vol. 120, No.5: 1160-1172 5. Vaskivuo T. Tumor Necrosis Factor-α, and NF-ĸB in Human Endometrial Hyperplasia and Carcinoma. Obstetric and Gynecology University of Oulu. 2002. 1463-1471 6. Boise et al. Bcl-x, a Bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74: 597-608 7. Busmianis I. Ho T, Tan S, Khoo K. P53 and Bcl-2 Expression in Invasive and Pre-Invasive Uterine Papillary Serous Carcinoma and Atrophic Endometrium. Annual Academy Medicine Singapore. 2005:34:423-424 8. Loffe OB, Papadimetriou JC,et al. Correlation of proliferation indices,apoptosis, and related oncogene expression (bcl-2 and c-erbb- 2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29(10):1150-9 9. Kokawa K, Yagi S, et al. Apoptosis andthe expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium. Hum Reprod 2001;16:2211-18 10. Gewies A. Introduction to Apoptosis. Aporeview. 2003: 1-26. 11. Bronchud, M.H., 2004. BCL2 in : Principle of Molecular Oncology, 2nd Ed. Humana Press. p. 82-85. 56
12. Elmore S, Apoptosis : Riview of programmed cell death. Toxicol Patol, 2007; 2007; 35 (4): 495 516 13. Ignae HF, Peter H.K, death and anti death : resistance to apoptosis, Nature review.2002. Vol 2: 277 288 14. Sheau, Y. S and Aaron J.W.H., 2000. Tissue specific bcl-2 protein partners in apoptosis: An ovarian paradigm. Physiological review vol 80, No 2, pp. 593-610 15. Walensky, L.D., 2008. Multimodal Targeting of the BCL-2 family in Cancer. American Association for Cancer Research Education Book. http://educationbook.aacrjournals.org 16. Taylor R, Sean P, Seamous J. Apoptosis : Controlloed demolition at the cellular level. Nature review. 2008. Vol 9.231 241 17. Yoshimura S, Banno T et al. Ceramid Formation Leads to Caspase 3 Activation During Hypoxic PC12 Cell Death. Inhibitory Effect of Bcl-2 oncerami Formation and Caspase-3 Activation. J.Biol.Chem.273:6921-6927 18. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178-94 19. Chang H.Y and Yang X 2000. Proteases for cell Suicide : Functions and regulation of caspase. Microbiol. Mol.Biol. Rev.64:821-846 20. Wong R.S Apoptosis in cancer : from pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research, 2011,30 :87 21. De vita, Rosenberg S. Cancer Principal & Practice of oncology Book 1,7 th. Lippincot William and Wilkins,@ 005 : 95 102 22. Rautureau, G.J.P., Catherine, L., Mark, G. H,. 2010. Intrinsically Disordered Proteins in Bcl-2 Regulated Apoptosis. International Journal Molecular Sciences,11 :1808-1824. 23. Kumar, Robbins, Leonard, S., Vinay, 2010. Neoplasia in: Robbins&Cotran Pathologic Basis of Disease, 8th ed. Philadelphia: Saunders Elsevier: 269-342. 57
24. Daniel N.N, Krosmeyer, S.J 2004. Cell death : Critical control Points Cell.116 : 205-219 25. Cory, S. and Adams, J.M., 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2, pp. 647. 26. Guset G et al. Bcl-2 Expression in Endometrial Carcinoma in Relation to Different Histopathologic Prognostic Factors. Journal of Experimental Medical Surgical Research. 2010: 251-254. Bcl 2 inhibit onkogen 27. Krysko D, Berghe T, Herde K, Vandenabeele P. Apoptosis and Necrosis: Detection, Discrimination and Phagocytosis. 2007. 205-220 28. Karunananda A. Management of Atypical Endometrial Hyperplasia. European International Journal of Applied Science and Technology. 2014. 1-5. 29. Steinbakk A et al. Molecular Biomarkers in Endometrial Hyperplasias Predict Cancer Progression. American Journal of Obstetric and Gynecology. 2011:375.e2. 30. Dorjgochoo T et al. Association of Genetic Markers in Bcl-2 Family of Apoptosis-Related Gees with Endometrial Cancer Risk in a Chinese Population. 2013: 1-2 31. Driak D. Changes in Expression of Some Apoptotic Markers in Different Types of Human Endometrium. Read periodical. 2011.1. 32. Elmer P. Image-based Quantification of Apoptosis-Driven Nuclear Fragmentation using the Opera. Perkin Elmer. USA. Jan 2010: 1-3. 33. Aylyyon.V, Cayla.X, et al. Bcl-2 Targets Protein Phosphatase 1α to Bad. TJOI. 2014: 1-9. 34. Boise et al. Bcl-x, a Bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993; 74: 597-608. 35. Sarmadi et al. Immunohistochemical expression of estrogen and progesterone receptors in endometrial hyperplasia and endometrioid carcinoma. Tehran University Medical Journal. 2012; 70 (3): 156-161. 58
36. Upson K,Allison K.H, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am. J. Obstet Gynecol. NIH. 2012; 207 (1): 36-38. 37. Dorjgochoo T,Xiang Y.B,et al. Association of Genetic Markers in the BCL-2 Family of Apoptosis-Related Genes with Endometrial Cancer Risk in a Chinese Population. PLOS. 2013; 8 (4): 1-9. 38. Cahyanti RD. Bcl-2 dan Indeks Apoptosis pada Hyperplasia Endometrium Non Atipik Simpleks dan Kompleks. Undip. 2008: 1-88 39. Barhoom S. Sharom A. Bcl-2 proteins link programmed cell death with growth and morphogenetic adaptations in the fungal plant pathogen Colletotrichum gloeosporioides. Departement of Plant Science. 2006; 22: 32-43. 40. Santoso D. Apoptosis Index Between Females And Males In Reguler Hemodialysis. Media Clinical Pathology and Medical Laboratory. 2013; 19 (3):P 1-2. 41. Teguh M. Mose J.C,et al. Perbedaan Indeks Apoptosis Plasenta Antara Preeklamsi dan Kehamilan Normal serta Hubungannya dengan Berat Badan Lahir dan Tekanan Darah Ibu. Bagian Obstetri dan Ginecologi. FK.Unpad. 2010; 42 (1): 1-5. 42. Gao G. Dou P. G1 Phase-Dependent Expression of Bcl-2 mrna and Protein Correlates with Chemoresistance of Human Cancer Cells. The American Society for Pharmacology and Experimental Therapeutics. 2000; 58 (5): 1-10. 43. Strik H. Deininger M.et al. BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry. 1999; 67: 763-768. 44. Ikegaki N, Katsumata M,et al. Expression of bcl-2 in Small Cell Lung Carcinoma Cells. American Association for cancer Research. February 2014; 54: 6-8. 59
45. Ribeiro M.D, Countinho L.M, The Role Of Apoptosis, Cell Proliferation Index, BCL-2, and P53 in Glioblastoma Prognosis. Arq Neuropsiquiatr. 2004; 62 (2): 262-270 46. Hardian et al. Apoptosis Index, Expression p53, Bcl-2,and Angiogenesis in Reccurence Endometrial Hyperplasia Patients. Undip 47. Marsden E Donald, Hacker F Neville. The Classification, Diagnosis and Management of Endometrial Hyperplasia. Review in Gynaecological faktor yang mempengaruhi Practice 3 (2003)89-97 48. Goncharenko et al. Predictive Diagnosis of Endometrial Hyperplasia and Personalized Therapeutic Strategy in Women of Fertile Age. The EPMA Journal. 2013: 14 49. Hannemann M, Alexander H, Cope N, Acheson N, Phillips A. Endometrial Hyperplasia: a Clinical s Review. Obstetrics, Gunaecology and Reproductive Medicine. 2014: 116-119 50. Allred D, Breast Center, Assestment of Prognostic and Predictive Factors in Breast Cancer by Immunohistochemistry. Baylor College of Medicine. (2006): 4-5 60